Only the highest dose eased treatment-resistant depression
What they did
Adults with treatment-resistant depression across ten countries received a single dose of synthetic psilocybin at 25mg, 10mg or 1mg, each alongside psychological support, with depression measured on the MADRS scale.
What they found
The 25mg group improved 6.6 points more than the 1mg comparison group at three weeks. The 10mg group did not separate from the comparison.
Worth knowing
Side effects were common, with 77 percent of all participants reporting headache, nausea or dizziness. Suicidal ideation and self-injury occurred in the 25mg group. A single dose and a three week window is a short look at a chronic condition.
Goodwin et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 2022.
Read the sourceKeep reading
depressionIn ordinary depression, psilocybin beat placebo by twelve pointsdepressionPsilocybin and a standard antidepressant, with no clear winnermeta-analysisPsilocybin survived the placebo correction, but the effect shrank to smallEvery trial in this section used a single large dose, given in a clinic, with trained people in the room for the whole session. That is a different activity from anything sold on this site. More on why that distinction matters.
For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.